From 2000 to 2019, definitive treatment for patients with intermediate- or high-risk prostate cancer and limited life expectancy increased.

At the same time, aggressive treatment declined in men with low-risk prostate cancer as might have been expected in an era ...

Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments ...

Screening men born with a high risk of developing prostate cancer, once they reach the age of 45, makes financial sense, a ...

This “watch-and-wait” approach is recommended for all prostate cancer patients who will likely die of some other cause, ...

In a study of US veterans, the authors say many would benefit from conservative management and active surveillance over ...

Medically reviewed by Amelia MacIntyre, DO Approximately 1 in 8 people with a prostate are diagnosed with prostate cancer ...

Prostate cancer treatment guidelines recommend against aggressive therapy for those with a life expectancy of less than 10 years.

Thumbs down for Roundup. Shocking research has revealed that more than a dozen chemicals used in popular weed killers like ...

“The MMAI risk classifier is a more precise and accurate prognosticator of metastasis than NCCN risk groups,” Dr Tward’s team wrote. “This approach aims to prevent both overtreatment and ...

When prostate cancer cells burst as a result of menadione treatment, there is no risk of metastasis ... However, the study ...